Coherus Oncology, Inc. (NASDAQ:CHRS) Receives $5.51 Consensus Target Price from Brokerages

Shares of Coherus Oncology, Inc. (NASDAQ:CHRS) have received an average rating of “Hold” from the five ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $5.5125.

A number of research firms have commented on CHRS. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a report on Saturday. Oppenheimer started coverage on shares of Coherus Oncology in a research report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price objective on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in CHRS. Geode Capital Management LLC raised its stake in Coherus Oncology by 0.8% during the 2nd quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company’s stock worth $1,958,000 after buying an additional 20,976 shares during the period. Panagora Asset Management Inc. grew its stake in Coherus Oncology by 17.8% in the fourth quarter. Panagora Asset Management Inc. now owns 1,620,271 shares of the biotechnology company’s stock valued at $2,301,000 after acquiring an additional 244,303 shares during the period. Hudson Bay Capital Management LP grew its stake in Coherus Oncology by 3.1% in the fourth quarter. Hudson Bay Capital Management LP now owns 835,000 shares of the biotechnology company’s stock valued at $1,186,000 after acquiring an additional 25,000 shares during the period. UBS Group AG increased its holdings in shares of Coherus Oncology by 38.5% during the third quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after acquiring an additional 221,410 shares in the last quarter. Finally, Tejara Capital Ltd increased its holdings in shares of Coherus Oncology by 1.7% during the second quarter. Tejara Capital Ltd now owns 698,770 shares of the biotechnology company’s stock valued at $511,000 after acquiring an additional 11,552 shares in the last quarter. 72.82% of the stock is owned by institutional investors and hedge funds.

Coherus Oncology Price Performance

Coherus Oncology stock opened at $1.63 on Friday. The stock has a market capitalization of $244.32 million, a price-to-earnings ratio of 1.12 and a beta of 1.05. Coherus Oncology has a 52-week low of $0.71 and a 52-week high of $2.62. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.45 and a current ratio of 1.47. The stock’s 50 day moving average price is $1.81 and its two-hundred day moving average price is $1.57.

Coherus Oncology (NASDAQ:CHRS) last released its quarterly earnings data on Monday, March 9th. The biotechnology company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.03). Coherus Oncology had a net margin of 398.42% and a negative return on equity of 860.29%. The company had revenue of $12.75 million during the quarter, compared to the consensus estimate of $14.09 million. On average, equities analysts predict that Coherus Oncology will post -1.05 earnings per share for the current year.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.